Patents Examined by Evelyn Y Pyla
  • Patent number: 10926001
    Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: February 23, 2021
    Assignee: PolarityTE, Inc.
    Inventor: Denver M. Lough
  • Patent number: 10928404
    Abstract: Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 23, 2021
    Assignees: The Brigham and Women's Hospital, Inc., The Board of Trustees of the Leland Stanford Junior University, Beth Israel Deaconess Medical Center
    Inventors: Utkan Demirci, Ionita Ghiran, Savas Tasoglu, Ronald W. Davis, Lars Steinmetz, Naside Gozde Durmus, Huseyin Cumhur Tekin
  • Patent number: 10913936
    Abstract: Provided herein are phenazine degrading agents, methods and systems for interfering with viability of bacteria and related antimicrobial and compositions.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: February 9, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Dianne K. Newman, Kyle C. Costa
  • Patent number: 10908170
    Abstract: Disclosed is a method for measuring a clotting time, including the steps of: (A) mixing a blood sample, an activator, a phospholipid, and a nickel ion-forming compound to obtain a specimen; and (B) mixing the specimen obtained in step (A) with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: February 2, 2021
    Assignees: SYSMEX CORPORATION, SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 10905799
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: February 2, 2021
    Assignees: Xenotherapeutics Corporation, Xenotherapeutics, Inc.
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Patent number: 10894065
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: January 19, 2021
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 10883084
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: January 5, 2021
    Assignees: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Patent number: 10876094
    Abstract: Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram/ml; ascorbic acid at a concentration range of about 400-600 microgram/ml, bFGF at a concentration range of about 50-200 ng/ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg/ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units/ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: December 29, 2020
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 10869900
    Abstract: The present invention relates to in vitro cultured senescent cells, such as epithelial cells, keratinocytes and/or fibroblasts as well as their use in the treatment of tissue regeneration, particularly for the treatment of wounds such as burns or ulcers or the treatment of inflammatory conditions. Optionally, products may be used in combination with further drugs including antimicrobial or antidiabetic agents.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 22, 2020
    Assignee: QRSkin GmbH
    Inventor: Martin Funk
  • Patent number: 10865385
    Abstract: The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: December 15, 2020
    Assignee: Stempeutics Research Pvt. Ltd.
    Inventors: Rakhi Pal, Pawan Kumar Gupta, Prasanna Kumar Kemburu, Jyothi Prasanna, Satish Totey, Raviraja Neelavar Seetharam, Umesh Baikunje Golithadka, Anish Sen Majumdar
  • Patent number: 10865386
    Abstract: Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: December 15, 2020
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Joong Hyun Shim, Seung Ha Yang, Tae Ryong Lee, Hak Hee Kang, Dong Wook Shin
  • Patent number: 10851344
    Abstract: The invention relates to devices, methods, kits, and compositions for in vitro generation of three-dimensional micro-tissues that are accurate models of heart, skeletal muscle, neuronal, and other tissues.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: December 1, 2020
    Assignees: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, The Regents of The University of California
    Inventors: Nathaniel Huebsch, Bruce Conklin, Kevin E. Healy, Peter Loskill
  • Patent number: 10851346
    Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: December 1, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATION
    Inventors: Chul Woo Yang, Mi-La Cho, Sung-Hwan Park, Eun Kyung Kim, Byung Ha Chung, Kyoung-Woon Kim, Seon-Yeong Lee, Sung-Hee Lee, Eun Ji Yang, Jeong-hee Jeong, Min Jung Park, Seok-Jung Kim, Eun-Jung Lee, Su-Jin Moon
  • Patent number: 10844349
    Abstract: The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 24, 2020
    Assignee: Albumedix Ltd.
    Inventors: Sandra Marie Merkel, Luke Dimasi, Collette Ann Sheahan, Philip Harvey Morton
  • Patent number: 10829740
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture is compatible with biologic function.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: November 10, 2020
    Assignee: Vivex Biologics Group, Inc.
    Inventors: Timothy Ganey, Wendy W. Weston, Miguel Quevedo, Stuart Oglesby, Gaetan Jean-Robert Delcroix, Paul C. Schiller, Gianluca D'Ippolito
  • Patent number: 10829739
    Abstract: The invention relates to progenitor cells of mesodermal lineage and their use in therapy.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 10, 2020
    Assignee: CELL THERAPY LIMITED
    Inventors: Thomas Averell Houze, Martin John Evans, Ajan Trevor Reginald, Ina Laura Pieper
  • Patent number: 10815459
    Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: October 27, 2020
    Assignees: K-STEMCELL CO., LTD.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Il Seob Shin
  • Patent number: 10806757
    Abstract: Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 20, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Thomas W. Gilbert, Michelle Manni, Tim D. Oury
  • Patent number: 10799614
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: October 13, 2020
    Assignees: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Patent number: 10791731
    Abstract: Systems for controlled freezing, storing and thawing a biological material in a bag and supporting apparatus. The systems are adapted to receive the biological material therein for freezing, storing, transporting and rapid thawing immediately prior to administration to a patient in need of the biological material.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 6, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Michael P. Chapman, Ernest Moore